Jacobs Levy Equity Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-62,225	Closed	-$732K	–	1052
2019 Q2	$732K	Sell	62,225 -23,400	-27%	-$283K	0.01%	688
2019 Q1	$1.17M	Buy	85,625 +40,100	+88%	+$520K	0.02%	626
2018 Q4	$467K	Buy	45,525 +20,900	+85%	+$268K	0.01%	743
2018 Q3	$410K	Buy	24,625 +10,925	+80%	+$197K	0.01%	818
2018 Q2	$216K	Buy	+13,700	New	+$208K	﹤0.01%	942
2018 Q1	–	Sell	-33,080	Closed	-$379K	–	1110
2017 Q4	$379K	Buy	+33,080	New	+$369K	0.01%	802

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's ALDR Position: Q3 2019 in Review

Jacobs Levy Equity Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 62,225 shares — an estimated $732K sold.

Jacobs Levy Equity Management first reported a position in ALDR in Q4 2017 and held it in 6 quarters. The position peaked at $1.17M in Q1 2019. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

Jacobs Levy Equity Management reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 62,225 Alder Biopharmaceuticals shares in Q3 2019, an estimated $732K.
Jacobs Levy Equity Management first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 6 quarters.
Jacobs Levy Equity Management's Alder Biopharmaceuticals position peaked at $1.17M in Q1 2019.
143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2019, filed 14 Nov 2019.